The Regeneron Pharmaceuticals story
What drives Regeneron Pharmaceuticals, what its price assumes and what could change the story, written from its own filings.
- Dupixent drives growth. Sanofi recorded $6.0 billion of global Dupixent sales in the quarter to June 2026, while Regeneron's Sanofi collaboration revenue increased 51%.
- The eye transition lags. EYLEA HD U.S. sales rose 52% in the quarter to June 2026, but combined U.S. sales of EYLEA HD and EYLEA declined 12%.
- Collaboration economics improve. Repayment of the Sanofi Development Balance by the end of June 2026 removes a deduction from collaboration revenue beginning in the third quarter of 2026.
